Sebastian Brandner

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7095197/publications.pdf

Version: 2024-02-01

		8732	9839
328	24,502	75	141
papers	citations	h-index	g-index

346	346	346	26734
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Humanized Transgenic Mice Are Resistant to Chronic Wasting Disease Prions From Norwegian Reindeer and Moose. Journal of Infectious Diseases, 2022, 226, 933-937.	1.9	25
2	Phenotyping clonal populations of glioma stem cell reveals a high degree of plasticity in response to changes of microenvironment. Laboratory Investigation, 2022, 102, 172-184.	1.7	7
3	CEST MRI provides amide/amine surrogate biomarkers for treatment-naÃ¯ve glioma sub-typing. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2377-2391.	3.3	12
4	Optical properties of human brain and tumour tissue: An ex vivo study spanning the visible range to beyond the second nearâ€infrared window. Journal of Biophotonics, 2022, 15, .	1.1	14
5	Targeting Macrophages and Synoviocytes Intracellular Milieu to Augment Antiâ€inflammatory Drug Potency. Advanced Therapeutics, 2022, 5, .	1.6	0
6	Multisystem screening reveals <scp>SARSâ€CoV</scp>â€2 in neurons of the myenteric plexus and in megakaryocytes. Journal of Pathology, 2022, 257, 198-217.	2.1	16
7	Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. Neuro-Oncology, 2022, 24, 1273-1285.	0.6	8
8	Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. The Cochrane Library, 2022, 2022, CD013387.	1.5	8
9	Diverse imaging features of adolescent glioblastoma. BJR|case Reports, 2022, 8, .	0.1	0
10	Diagnostic accuracy of 1p/19q codeletion tests in oligodendroglioma: A comprehensive metaâ€analysis based on a Cochrane systematic review. Neuropathology and Applied Neurobiology, 2022, 48, .	1.8	10
11	Distinct miRNA Expression Signatures of Primary and Secondary Central Nervous System Lymphomas. Journal of Molecular Diagnostics, 2022, 24, 224-240.	1.2	2
12	Prion protein monoclonal antibody (PRN100) therapy for Creutzfeldtâ€"Jakob disease: evaluation of a first-in-human treatment programme. Lancet Neurology, The, 2022, 21, 342-354.	4.9	38
13	Research Status of the Orphan G Protein Coupled Receptor 158 and Future Perspectives. Cells, 2022, 11, 1334.	1.8	6
14	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells. International Journal of Molecular Sciences, 2022, 23, 5238.	1.8	4
15	Iatrogenic cerebral amyloid angiopathy: an emerging clinical phenomenon. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 693-700.	0.9	26
16	ETMR-06. Molecular and clinical characteristics of CNS tumors withBCOR(L1) fusion/internal tandem duplication. Neuro-Oncology, 2022, 24, i50-i50.	0.6	2
17	RARE-15. Astroblastoma, MN1 altered comprises two molecularly and clinically distinct subgroups defined by the fusion partners BEND2 and CXXC5. Neuro-Oncology, 2022, 24, i12-i13.	0.6	1
18	Survival Outcomes and Prognostic Factors in Glioblastoma. Cancers, 2022, 14, 3161.	1.7	33

#	Article	IF	Citations
19	The Boston criteria version 2.0 for cerebral amyloid angiopathy: a multicentre, retrospective, MRIâ€“neuropathology diagnostic accuracy study. Lancet Neurology, The, 2022, 21, 714-725.	4.9	168
20	Imaging characteristics of H3 K27M histone-mutant diffuse midline glioma in teenagers and adults. Quantitative Imaging in Medicine and Surgery, 2021, 11, 43-56.	1.1	21
21	Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers. Neuropathology and Applied Neurobiology, 2021, 47, 471-487.	1.8	3
22	Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison. American Journal of Neuroradiology, 2021, 42, 441-447.	1.2	9
23	Prognostic value of test(s) for O6-methylguanineâ€“DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. The Cochrane Library, 2021, 2021, CD013316.	1.5	19
24	Potential of Magnetic Hyperthermia to Stimulate Localized Immune Activation. Small, 2021, 17, e2005241.	5.2	35
25	The white matter is a pro-differentiative niche for glioblastoma. Nature Communications, 2021, 12, 2184.	5.8	37
26	Glioblastomas acquire myeloid-affiliated transcriptional programs via epigenetic immunoediting to elicit immune evasion. Cell, 2021, 184, 2454-2470.e26.	13.5	165
27	MGMTpromoter methylation testing to predict overall survival in people with glioblastoma treated with temozolomide: a comprehensive meta-analysis based on a Cochrane Systematic Review. Neuro-Oncology, 2021, 23, 1457-1469.	0.6	36
28	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. Acta Neuropathologica, 2021, 142, 179-189.	3.9	24
29	Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nature Communications, 2021, 12, 2148.	5.8	20
30	Cross-Species Genomics Reveals Oncogenic Dependencies in ZFTA/C11orf95 Fusionâ€“Positive Supratentorial Ependymomas. Cancer Discovery, 2021, 11, 2230-2247.	7.7	39
31	Alzheimerâ€™s disease neuropathological change three decades after iatrogenic amyloid-Î²2 transmission. Acta Neuropathologica, 2021, 142, 211-215.	3.9	17
32	Molecular Diagnostics of Adult Gliomas in Neuropathological Practice. Acta Medica Academica, 2021, 50, 29.	0.3	5
33	Microcystic Cerebral Neoplasm in a Nilgai Antelope (Boselaphus tragocamelus): Putative Microcystic Meningioma. Journal of Comparative Pathology, 2021, 186, 69-72.	0.1	0
34	Genomic Prognosticators and Extent of Resection in Molecularly Subtyped World Health Organization Grade II and III Gliomasâ€“A Single-Institution, Nine-Year Data. World Neurosurgery, 2021, 151, e217-e233.	0.7	4
35	Recurrent fusions in PLAGL1 define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. Acta Neuropathologica, 2021, 142, 827-839.	3.9	33
36	Filtration-Histogram Based Magnetic Resonance Texture Analysis (MRTA) for the Distinction of Primary Central Nervous System Lymphoma and Glioblastoma. Journal of Personalized Medicine, 2021, 11, 876.	1.1	6

#	Article	IF	Citations
37	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	5.8	237
38	Clear cell meningiomas are defined by a highly distinct DNA methylation profile and mutations in SMARCE1. Acta Neuropathologica, 2021, 141, 281-290.	3.9	31
39	Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. Nature Communications, 2021, 12, 6130.	5.8	14
40	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. Journal of Clinical Oncology, 2021, 39, 3839-3852.	0.8	93
41	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. Acta Neuropathologica, 2020, 139, 193-209.	3.9	83
42	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. Acta Neuropathologica, 2020, 139, 403-406.	3.9	9
43	Frequent alterations in p16/CDKN2A identified by immunohistochemistry and FISH in chordoma. Journal of Pathology: Clinical Research, 2020, 6, 113-123.	1.3	39
44	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 176-183.	0.9	33
45	Seizure outcomes and survival in adult low-grade glioma over 11 years: living longer and better. Neuro-Oncology Practice, 2020, 7, 196-201.	1.0	9
46	Invited Review: The role of prionâ€like mechanisms in neurodegenerative diseases. Neuropathology and Applied Neurobiology, 2020, 46, 522-545.	1.8	72
47	Risk of Transmissibility From Neurodegenerative Disease-Associated Proteins: Experimental Knowns and Unknowns. Journal of Neuropathology and Experimental Neurology, 2020, 79, 1141-1146.	0.9	24
48	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. Cell, 2020, 183, 1617-1633.e22.	13.5	93
49	PiggyBac mutagenesis and exome sequencing identify genetic driver landscapes and potential therapeutic targets of EGFR-mutant gliomas. Genome Biology, 2020, 21, 181.	3.8	18
50	Peripheral nerve neurolymphomatosis: Clinical features, treatment, and outcomes. Muscle and Nerve, 2020, 62, 617-625.	1.0	19
51	Potential human transmission of amyloid Î² pathology: surveillance and risks. Lancet Neurology, The, 2020, 19, 872-878.	4.9	46
52	Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurology, The, 2020, 19, 840-848.	4.9	42
53	Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLoS Biology, 2020, 18, e3000725.	2.6	13
54	Bi-allelic JAM2 Variants Lead to Early-Onset Recessive Primary Familial Brain Calcification. American Journal of Human Genetics, 2020, 106, 412-421.	2.6	47

#	Article	IF	Citations
55	Noninvasive diffusion magnetic resonance imaging of brain tumour cell size for the early detection of therapeutic response. Scientific Reports, 2020, 10, 9223.	1.6	29
56	Clinical characteristics, risk factors, and outcomes of POEMS syndrome. Neurology, 2020, 95, e268-e279.	1.5	28
57	Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status. BMC Medical Informatics and Decision Making, 2020, 20, 149.	1.5	38
58	Microvascular injury and hypoxic damage: emerging neuropathological signatures in COVID-19. Acta Neuropathologica, 2020, 140, 397-400.	3.9	85
59	Polycomb-mediated repression of EphrinA5 promotes growth and invasion of glioblastoma. Oncogene, 2020, 39, 2523-2538.	2.6	18
60	Fulminant corticobasal degeneration: a distinct variant with predominant neuronal tau aggregates. Acta Neuropathologica, 2020, 139, 717-734.	3.9	15
61	Prevalence in Britain of abnormal prion protein in human appendices before and after exposure to the cattle BSE epizootic. Acta Neuropathologica, 2020, 139, 965-976.	3.9	30
62	In vitro performance of combinations of anti-siphon devices with differential pressure valves in relation to the spatial position. Acta Neurochirurgica, 2020, 162, 1033-1040.	0.9	2
63	World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. Radiology, 2020, 296, 111-121.	3.6	62
64	Microglia promote glioblastoma via mTORâ€mediated immunosuppression of the tumour microenvironment. EMBO Journal, 2020, 39, e103790.	3.5	77
65	Mutant IDH Sensitizes Gliomas to Endoplasmic Reticulum Stress and Triggers Apoptosis via miR-183-Mediated Inhibition of Semaphorin 3E. Cancer Research, 2019, 79, 4994-5007.	0.4	28
66	MYCN amplification drives an aggressive form of spinal ependymoma. Acta Neuropathologica, 2019, 138, 1075-1089.	3.9	104
67	Redistribution of <scp>EZH</scp> 2 promotes malignant phenotypes by rewiring developmental programmes. EMBO Reports, 2019, 20, e48155.	2.0	9
68	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	2.4	37
69	On the journey to uncover the causes of selective cellular and regional vulnerability in neurodegeneration. Acta Neuropathologica, 2019, 138, 677-680.	3.9	7
70	Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain, 2019, 142, 760-770.	3.7	16
71	Amyloid Î² oligomers constrict human capillaries in Alzheimerâ€™s disease via signaling to pericytes. Science, 2019, 365, .	6.0	436
72	Rosette-forming glioneuronal tumors share a distinct DNA methylation profile and mutations in FGFR1, with recurrent co-mutation of PIK3CA and NF1. Acta Neuropathologica, 2019, 138, 497-504.	3.9	57

#	Article	IF	Citations
73	Autosomal dominant optic atrophy and cataract â€œplusâ€•phenotype including axonal neuropathy. Neurology: Genetics, 2019, 5, e322.	0.9	12
74	Modelling MR and clinical features in grade II/III astrocytomas to predict IDH mutation status. European Journal of Radiology, 2019, 114, 120-127.	1.2	21
75	Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre. Acta Neuropathologica Communications, 2019, 7, 24.	2.4	101
76	Filtration-histogram based magnetic resonance texture analysis (MRTA) for glioma IDH and 1p19q genotyping. European Journal of Radiology, 2019, 113, 116-123.	1.2	30
77	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. Acta Neuropathologica, 2019, 137, 837-846.	3.9	43
78	Diagnostic test accuracy and cost-effectiveness of tests for codeletion of chromosomal arms 1p and 19q in people with glioma. The Cochrane Library, 2019, , .	1.5	1
79	Early onset cerebral amyloid angiopathy following childhood exposure to cadaveric dura. Annals of Neurology, 2019, 85, 284-290.	2.8	54
80	<scp>IDH</scp> mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers. Neuropathology and Applied Neurobiology, 2019, 45, 91-94.	1.8	4
81	Transmissible human proteopathies: an expanding field. Diagnostic Histopathology, 2019, 25, 16-22.	0.2	7
82	Familial Creutzfeldt-Jakob disease in an Indian kindred. Annals of Indian Academy of Neurology, 2019, 22, 458.	0.2	6
83	Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. Scientific Reports, 2018, 8, 6108.	1.6	52
84	Evidence of amyloid-Î² cerebral amyloid angiopathy transmission through neurosurgery. Acta Neuropathologica, 2018, 135, 671-679.	3.9	80
85	A diagnostic conundrum. Practical Neurology, 2018, 18, 137-142.	0.5	1
86	Experimental sheep BSE prions generate the vCJD phenotype when serially passaged in transgenic mice expressing human prion protein. Journal of the Neurological Sciences, 2018, 386, 4-11.	0.3	6
87	Inhibition of GPR158 by microRNA-449a suppresses neural lineage of glioma stem/progenitor cells and correlates with higher glioma grades. Oncogene, 2018, 37, 4313-4333.	2.6	21
88	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
89	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	3.9	190
90	Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. European Radiology, 2018, 28, 3779-3788.	2.3	58

#	Article	IF	Citations
91	Neurological update: gliomas and other primary brain tumours in adults. Journal of Neurology, 2018, 265, 717-727.	1.8	24
92	THREE-DIMENSIONAL MULTICOLOUR LINEAGE TRACING OF INTRINSIC BRAIN TUMOUR MODELS. Neuro-Oncology, 2018, 20, v348-v348.	0.6	0
93	Transmission of amyloid-Î² protein pathology from cadaveric pituitary growth hormone. Nature, 2018, 564, 415-419.	13.7	122
94	Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathologica, 2018, 136, 793-803.	3.9	195
95	Evaluating the causality of novel sequence variants in the prion protein gene by example. Neurobiology of Aging, 2018, 71, 265.e1-265.e7.	1.5	9
96	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	3.9	118
97	Fetal gene therapy for neurodegenerative disease of infants. Nature Medicine, 2018, 24, 1317-1323.	15.2	117
98	Variant Creutzfeldtâ€“Jakob Disease in a Patient with Heterozygosity at PRNP Codon 129. New England Journal of Medicine, 2017, 376, 292-294.	13.9	127
99	Leprosy in a patient infected with HIV. Practical Neurology, 2017, 17, 135-139.	0.5	4
100	Prion disease: experimental models and reality. Acta Neuropathologica, 2017, 133, 197-222.	3.9	54
101	Neurological outcome and frequency of overdrainage in normal pressure hydrocephalus directly correlates with implanted ventriculo-peritoneal shunt valve type. Neurological Research, 2017, 39, 601-605.	0.6	17
102	MAPK pathway activation in the embryonic pituitary results in stem cell compartment expansion, differentiation defects and provides insights into the pathogenesis of papillary craniopharyngioma. Development (Cambridge), 2017, 144, 2141-2152.	1.2	58
103	Deletion of P2 promoter of GJB1 gene a cause of Charcot-Marie-Tooth disease. Neuromuscular Disorders, 2017, 27, 766-770.	0.3	6
104	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. Acta Neuropathologica, 2017, 133, 325-327.	3.9	12
105	H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. Cancer Cell, 2017, 32, 684-700.e9.	7.7	192
106	Myostatin inhibition prevents skeletal muscle pathophysiology in Huntingtonâ€™s disease mice. Scientific Reports, 2017, 7, 14275.	1.6	27
107	The driver landscape of sporadic chordoma. Nature Communications, 2017, 8, 890.	5.8	115
108	Methods for Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2017, 1658, 311-346.	0.4	17

#	Article	IF	Citations
109	A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS. Cell Reports, 2017, 20, 411-426.	2.9	49
110	Neuronal and Peripheral Pentraxins Modify Glutamate Release and may Interact in Bloodâ€“Brain Barrier Failure. Cerebral Cortex, 2017, 27, 3437-3448.	1.6	34
111	Imaging features of spinal tanycytic ependymoma. Neuroradiology Journal, 2016, 29, 61-65.	0.6	10
112	Early CSF and Serum S100B Concentrations for Outcome Prediction in Traumatic Brain Injury and Subarachnoid Hemorrhage. Clinical Neurology and Neurosurgery, 2016, 145, 79-83.	0.6	51
113	The pathological diagnosis of nerve biopsies: a practical approach. Diagnostic Histopathology, 2016, 22, 333-344.	0.2	4
114	Collinge et al. reply. Nature, 2016, 535, E2-E3.	13.7	3
115	Collinge et al. reply. Nature, 2016, 537, E9-E9.	13.7	1
116	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	3.7	170
117	Imatinib and Nilotinib increase glioblastoma cell invasion via Abl-independent stimulation of p130Cas and FAK signalling. Scientific Reports, 2016, 6, 27378.	1.6	37
118	Deficiency of the zinc finger protein ZFP106 causes motor and sensory neurodegeneration. Human Molecular Genetics, 2016, 25, 291-307.	1.4	19
119	Prion-mediated neurodegeneration is associated with early impairment of the ubiquitinâ€“proteasome system. Acta Neuropathologica, 2016, 131, 411-425.	3.9	51
120	Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular AÎ² amyloid depositsin vivo. Open Biology, 2016, 6, 150202.	1.5	21
121	Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. JAMA Neurology, 2016, 73, 447.	4.5	41
122	Evolution of Diffusion-Weighted Magnetic Resonance Imaging Signal Abnormality in Sporadic Creutzfeldt-Jakob Disease, With Histopathological Correlation. JAMA Neurology, 2016, 73, 76.	4.5	60
123	Hereditary leukoencephalopathy with axonal spheroids: a spectrum of phenotypes from CNS vasculitis to parkinsonism in an adult onset leukodystrophy series. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 512-519.	0.9	58
124	Quantitative in vivo optical tomography of cancer progression & vasculature development in adult zebrafish. Oncotarget, 2016, 7, 43939-43948.	0.8	23
125	9â€¦Creation of a large collection of frozen sections using an online database; a novel application of virtual pathology. , 2016, , .		0
126	Identification of clinical target areas in the brainstem of prionâ€infected mice. Neuropathology and Applied Neurobiology, 2015, 41, 613-630.	1.8	11

#	Article	IF	Citations
127	A systematic investigation of production of synthetic prions from recombinant prion protein. Open Biology, 2015, 5, 150165.	1.5	39
128	Generation of brain tumours by Cre-mediated recombination of neural progenitorsin situwith the tamoxifen metabolite endoxifen. DMM Disease Models and Mechanisms, 2015, 9, 211-20.	1.2	9
129	Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. Journal of Pathology, 2015, 237, 363-378.	2.1	98
130	Transmission Properties of Human PrP 102L Prions Challenge the Relevance of Mouse Models of GSS. PLoS Pathogens, 2015, 11, e1004953.	2.1	27
131	A novel and rapid method for obtaining high titre intact prion strains from mammalian brain. Scientific Reports, 2015, 5, 10062.	1.6	51
132	Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy. Neuromuscular Disorders, 2015, 25, 511-515.	0.3	26
133	A naturally occurring variant of the human prion protein completely prevents prion disease. Nature, 2015, 522, 478-481.	13.7	144
134	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. Neuropathology and Applied Neurobiology, 2015, 41, 694-720.	1.8	83
135	A novel SOD1-ALS mutation separates central and peripheral effects of mutant SOD1 toxicity. Human Molecular Genetics, 2015, 24, 1883-1897.	1.4	52
136	Inhibition of oxidative metabolism leads to p53 genetic inactivation and transformation in neural stem cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 1059-1064.	3.3	63
137	World Health Organization grade III meningiomas. A retrospective study for outcome and prognostic factors assessment. British Journal of Neurosurgery, 2015, 29, 693-698.	0.4	41
138	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. Acta Neuropathologica, 2015, 130, 407-417.	3.9	237
139	Iatrogenic CJD due to pituitary-derived growth hormone with genetically determined incubation times of up to 40 years. Brain, 2015, 138, 3386-3399.	3.7	92
140	PERIPHERAL NERVE BING-NEEL SYNDROME. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.59-e4.	0.9	3
141	A novel HTRA1 exon 2 mutation causes loss of protease activity in a Pakistani CARASIL patient. Journal of Neurology, 2015, 262, 1369-1372.	1.8	17
142	MRI detection of prion protein plaques in variant Creutzfeldt-Jakob disease. Neurology, 2015, 84, 1498-1499.	1.5	3
143	Evidence for human transmission of amyloid-Î² pathology and cerebral amyloid angiopathy. Nature, 2015, 525, 247-250.	13.7	418
144	A Nonsense Mutation in Mouse Tardbp Affects TDP43 Alternative Splicing Activity and Causes Limb-Clasping and Body Tone Defects. PLoS ONE, 2014, 9, e85962.	1.1	18

#	Article	IF	Citations
145	Ventricular and Lumbar Cerebrospinal Fluid Concentrations of Alzheimer's Disease Biomarkers in Patients with Normal Pressure Hydrocephalus and Posttraumatic Hydrocephalus. Journal of Alzheimer's Disease, 2014, 41, 1057-1062.	1.2	33
146	Truncating and Missense Mutations in IGHMBP2 Cause Charcot-Marie Tooth Disease Type 2. American Journal of Human Genetics, 2014, 95, 590-601.	2.6	75
147	Peripheral Administration of a Humanized Anti-PrP Antibody Blocks Alzheimer's Disease AÎ²2 Synaptotoxicity. Journal of Neuroscience, 2014, 34, 6140-6145.	1.7	68
148	Treatable childhood neuronopathy caused by mutations in riboflavin transporter RFVT2. Brain, 2014, 137, 44-56.	3.7	143
149	Novel C12orf65 mutations in patients with axonal neuropathy and optic atrophy. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 486-492.	0.9	35
150	O03 * IDH1 MUTATIONS IN NEURAL STEM CELLS PROMOTE MIGRATION AND INVASION AND ACT SYNERGISTICALLY WITH P53 AND PTEN LOSS IN MURINE TUMOUR CELLS. Neuro-Oncology, 2014, 16, vi13-vi13.	0.6	0
151	High-throughput, automated quantification of white matter neurons in mild malformation of cortical development in epilepsy. Acta Neuropathologica Communications, 2014, 2, 72.	2.4	24
152	White matter perivascular spaces. Neurology, 2014, 82, 57-62.	1.5	151
153	Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nature Communications, 2014, 5, 4347.	5.8	126
154	A crucial role for DOK1 in PDGF-BB-stimulated glioma cell invasion through p130Cas and Rap1 signalling. Journal of Cell Science, 2014, 127, 3397-3397.	1.2	5
155	Microglial Cx3cr1knockout reduces prion disease incubation time in mice. BMC Neuroscience, 2014, 15, 44.	0.8	28
156	Extended phenotypic spectrum of KIF5A mutations. Neurology, 2014, 83, 612-619.	1.5	92
157	Critical role for DOK1 in PDGF-BB stimulated glioma cell invasion via p130Cas and Rap1 signalling. Journal of Cell Science, 2014, 127, 2647-58.	1.2	15
158	Active and Silent Thyroid-Stimulating Hormoneâ^'Expressing Pituitary Adenomas: Presenting Symptoms, Treatment, Outcomes, and Recurrence. World Neurosurgery, 2014, 82, 1224-1231.	0.7	40
159	Variant Creutzfeldt-Jakob Disease With Extremely Low Lymphoreticular Deposition of Prion Protein. JAMA Neurology, 2014, 71, 340.	4.5	17
160	Mitochondria and Quality Control Defects in a Mouse Model of Gaucher Diseaseâ€"Links to Parkinsonâ€™s Disease. Cell Metabolism, 2013, 17, 941-953.	7.2	277
161	Filamentous white matter prion protein deposition is a distinctive feature of multiple inherited prion diseases. Acta Neuropathologica Communications, 2013, 1, 8.	2.4	7
162	A Novel Prion Disease Associated with Diarrhea and Autonomic Neuropathy. New England Journal of Medicine, 2013, 369, 1904-1914.	13.9	113

#	Article	IF	Citations
163	Rapidly progressive asymmetrical weakness in Charcotâ€“Marieâ€“Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy. Neuromuscular Disorders, 2013, 23, 399-403.	0.3	38
164	Epigenetic Regulation of Survivin by Bmi1 Is Cell Type Specific During Corticogenesis and in Gliomas. Stem Cells, 2013, 31, 190-202.	1.4	25
165	The autophagy-associated factors DRAM1 and p62 regulate cell migration and invasion in glioblastoma stem cells. Oncogene, 2013, 32, 699-712.	2.6	224
166	Asymmetric sensory ganglionopathy: A case series. Muscle and Nerve, 2013, 48, 145-150.	1.0	10
167	Atypical Scrapie Prions from Sheep and Lack of Disease in Transgenic Mice Overexpressing Human Prion Protein. Emerging Infectious Diseases, 2013, 19, 1731-1739.	2.0	27
168	Inherited Prion Disease A117V Is Not Simply a Proteinopathy but Produces Prions Transmissible to Transgenic Mice Expressing Homologous Prion Protein. PLoS Pathogens, 2013, 9, e1003643.	2.1	46
169	Prevalent abnormal prion protein in human appendixes after bovine spongiform encephalopathy epizootic: large scale survey. BMJ, The, 2013, 347, f5675-f5675.	3.0	246
170	Neuroprotein Dynamics in the Cerebrospinal Fluid: Intraindividual Concomitant Ventricular and Lumbar Measurements. European Neurology, 2013, 70, 189-194.	0.6	30
171	Brain-Derived Protein Concentrations in the Cerebrospinal Fluid: Contribution of Trauma Resulting from Ventricular Drain Insertion. Journal of Neurotrauma, 2013, 30, 1205-1210.	1.7	16
172	Comparative Expression Analysis Reveals Lineage Relationships between Human and Murine Gliomas and a Dominance of Glial Signatures during Tumor Propagation In Vitro. Cancer Research, 2013, 73, 5834-5844.	0.4	28
173	Sod1 Deficiency Reduces Incubation Time in Mouse Models of Prion Disease. PLoS ONE, 2013, 8, e54454.	1.1	22
174	Mouse Models of Glioma Pathogenesis: History and State of the Art. , 2013, , 87-107.		0
175	Plasmacytoid Dendritic Cells Sequester High Prion Titres at Early Stages of Prion Infection. PLoS Pathogens, 2012, 8, e1002538.	2.1	41
176	Overexpression of the Hspa13 (Stch) gene reduces prion disease incubation time in mice. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 13722-13727.	3.3	21
177	PrP Antibodies Do Not Trigger Mouse Hippocampal Neuron Apoptosis. Science, 2012, 335, 52-52.	6.0	62
178	Mutation in FAM134B causing severe hereditary sensory neuropathy: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 119-120.	0.9	48
179	Progressive neuronal inclusion formation and axonal degeneration in CHMP2B mutant transgenic mice. Brain, 2012, 135, 819-832.	3.7	97
180	Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. Journal of Neurology, 2012, 259, 1673-1685.	1.8	82

#	Article	IF	Citations
181	Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiology of Aging, 2012, 33, 828.e31-828.e44.	1.5	54
182	Diagnostic implications of histological analysis of neurosurgical aspirate in addition to routine resections. Neuropathology, 2012, 32, 44-50.	0.7	6
183	BAG3 mutations: another cause of giant axonal neuropathy. Journal of the Peripheral Nervous System, 2012, 17, 210-216.	1.4	66
184	Shunt-Dependent Hydrocephalus Following Subarachnoid Hemorrhage Correlates with Increased S100B Levels in Cerebrospinal Fluid and Serum. Acta Neurochirurgica Supplementum, 2012, 114, 217-220.	0.5	16
185	Processing of nerve biopsies: A practical guide for neuropathologists. , 2012, 31, 7-23.		56
186	Structural correlates of active-staining following magnetic resonance microscopy in the mouse brain. NeuroImage, 2011, 56, 974-983.	2.1	28
187	Variable phenotypes are associated with PMP22 missense mutations. Neuromuscular Disorders, 2011, 21, 106-114.	0.3	48
188	Sex Effects in Mouse Prion Disease Incubation Time. PLoS ONE, 2011, 6, e28741.	1.1	13
189	One Hundred and One Dysembryoplastic Neuroepithelial Tumors: An Adult Epilepsy Series With Immunohistochemical, Molecular Genetic, and Clinical Correlations and a Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2011, 70, 859-878.	0.9	125
190	A novel mutation in the nerveâ€specific 5â€²UTR of the GJB1 gene causes Xâ€linked Charcotâ€Marieâ€Tooth disease. Journal of the Peripheral Nervous System, 2011, 16, 65-70.	1.4	24
191	c-Jun expression in human neuropathies: a pilot study. Journal of the Peripheral Nervous System, 2011, 16, 295-303.	1.4	51
192	Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo. Oncogene, 2011, 30, 1341-1350.	2.6	34
193	Tau, prions and Aî²: the triad of neurodegeneration. Acta Neuropathologica, 2011, 121, 5-20.	3.9	84
194	Diversity of prion diseases: (no) strains attached?. Acta Neuropathologica, 2011, 121, 1-4.	3.9	6
195	Effect of fixation on brain and lymphoreticular vCJD prions and bioassay of key positive specimens from a retrospective vCJD prevalence study. Journal of Pathology, 2011, 223, 511-518.	2.1	22
196	Sarcoidosis presenting as acute inflammatory demyelinating polyradiculoneuropathy. Muscle and Nerve, 2011, 43, 296-298.	1.0	10
197	Inherited prion disease with 4-octapeptide repeat insertion: disease requires the interaction of multiple genetic risk factors. Brain, 2011, 134, 1829-1838.	3.7	29
198	Behavioral and Other Phenotypes in a Cytoplasmic Dynein Light Intermediate Chain 1 Mutant Mouse. Journal of Neuroscience, 2011, 31, 5483-5494.	1.7	23

#	Article	IF	Citations
199	A standardized comparison of commercially available prion decontamination reagents using the Standard Steel-Binding Assay. Journal of General Virology, 2011, 92, 718-726.	1.3	26
200	Brain biopsy in dementia: clinical indications and diagnostic approach. Acta Neuropathologica, 2010, 120, 327-341.	3.9	64
201	In the Human Urothelium and Suburothelium, Intradetrusor Botulinum Neurotoxin Type A Does Not Induce Apoptosis: Preliminary Results. European Urology, 2010, 57, 879-883.	0.9	11
202	Effects of formalin fixation on magnetic resonance indices in multiple sclerosis cortical gray matter. Journal of Magnetic Resonance Imaging, 2010, 32, 1054-1060.	1.9	28
203	Earlyâ€onset Lâ€dopaâ€responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations. Movement Disorders, 2010, 25, 1791-1800.	2.2	287
204	Generation of a panel of antibodies against proteins encoded on human chromosome 21. Journal of Negative Results in BioMedicine, 2010, 9, 7.	1.4	0
205	Largeâ€scale immunohistochemical examination for lymphoreticular prion protein in tonsil specimens collected in Britain. Journal of Pathology, 2010, 222, 380-387.	2.1	48
206	Peripheral Nerve Society Guideline on processing and evaluation of nerve biopsies. Journal of the Peripheral Nervous System, 2010, 15, 164-175.	1.4	66
207	Bortezomibâ€induced inflammatory neuropathy. Journal of the Peripheral Nervous System, 2010, 15, 366-368.	1.4	32
208	Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. Oncogene, 2010, 29, 335-344.	2.6	86
209	Combinations of genetic mutations in the adult neural stem cell compartment determine brain tumour phenotypes. EMBO Journal, 2010, 29, 222-235.	3.5	192
210	Nanog, Gli, and p53: a new network of stemness in development and cancer. EMBO Journal, 2010, 29, 2475-2476.	3.5	28
211	Fbw7 controls neural stem cell differentiation and progenitor apoptosis via Notch and c-Jun. Nature Neuroscience, 2010, 13, 1365-1372.	7.1	158
212	Chronic wasting disease prions are not transmissible to transgenic mice overexpressing human prion protein. Journal of General Virology, 2010, 91, 2651-2657.	1.3	106
213	PAW35 Anti-prion protein monoclonal antibodies at low doses effectively treat prion disease in mice without side-effects. Journal of Neurology, Neurosurgery and Psychiatry, 2010, 81, e33-e33.	0.9	1
214	High field (9.4 Tesla) magnetic resonance imaging of cortical grey matter lesions in multiple sclerosis. Brain, 2010, 133, 858-867.	3.7	138
215	Disruption of endocytic trafficking in frontotemporal dementia with CHMP2B mutations. Human Molecular Genetics, 2010, 19, 2228-2238.	1.4	163
216	Magnetization transfer ratio may be a surrogate of spongiform change in human prion diseases. Brain, 2010, 133, 3058-3068.	3.7	10

#	Article	IF	Citations
217	Heterozygosity at Polymorphic Codon 219 in Variant Creutzfeldt-Jakob Disease. Archives of Neurology, 2010, 67, 1021-3.	4.9	19
218	Spontaneous generation of mammalian prions. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 14402-14406.	3.3	40
219	An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. DMM Disease Models and Mechanisms, 2009, 2, 359-373.	1.2	91
220	Suburothelial Myofibroblasts in the Human Overactive Bladder and the Effect of Botulinum Neurotoxin Type A Treatment. European Urology, 2009, 55, 1440-1449.	0.9	74
221	Sevenâ€year discordance in age at onset in monozygotic twins with inherited prion disease (P102L). Neuropathology and Applied Neurobiology, 2009, 35, 427-432.	1.8	12
222	Cadherin-11 Up-Regulation in Overactive Bladder Suburothelial Myofibroblasts. Journal of Urology, 2009, 182, 190-195.	0.2	15
223	Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins. Journal of General Virology, 2009, 90, 546-558.	1.3	58
224	Lack of TARâ€DNA binding proteinâ€43 (TDPâ€43) pathology in human prion diseases. Neuropathology and Applied Neurobiology, 2008, 34, 446-456.	1.8	21
225	The origin of the prion agent of kuru: molecular and biological strain typing. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3747-3753.	1.8	39
226	Single treatment with RNAi against prion protein rescues early neuronal dysfunction and prolongs survival in mice with prion disease. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 10238-10243.	3.3	174
227	Kuru prions and sporadic Creutzfeldtâ€“Jakob disease prions have equivalent transmission properties in transgenic and wild-type mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 3885-3890.	3.3	62
228	Investigation ofMcp1as a Quantitative Trait Gene for Prion Disease Incubation Time in Mouse. Genetics, 2008, 180, 559-566.	1.2	23
229	A clinical study of kuru patients with long incubation periods at the end of the epidemic in Papua New Guinea. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3725-3739.	1.8	65
230	Central and peripheral pathology of kuru: pathological analysis of a recent case and comparison with other forms of human prion disease. Philosophical Transactions of the Royal Society B: Biological Sciences, 2008, 363, 3755-3763.	1.8	47
231	Phenotypic heterogeneity and genetic modification of P102L inherited prion disease in an international series. Brain, 2008, 131, 2632-2646.	3.7	126
232	First Report of Creutzfeldt-Jakob Disease Occurring in 2 Siblings Unexplained byPRNPMutation. Journal of Neuropathology and Experimental Neurology, 2008, 67, 838-841.	0.9	11
233	Molecular Diagnosis of Human Prion Disease. Methods in Molecular Biology, 2008, 459, 197-227.	0.4	38
234	Prion infectivity in variant Creutzfeldt-Jakob disease rectum. Gut, 2007, 56, 90-94.	6.1	28

#	Article	IF	Citations
235	Targeting Cellular Prion Protein Reverses Early Cognitive Deficits and Neurophysiological Dysfunction in Prion-Infected Mice. Neuron, 2007, 53, 325-335.	3.8	246
236	Hyperphosphorylation of tau and neurofilaments and activation of CDK5 and ERK1/2 in PTEN-deficient cerebella. Molecular and Cellular Neurosciences, 2007, 34, 400-408.	1.0	19
237	An additional human chromosome 21 causes suppression of neural fate of pluripotent mouse embryonic stem cells in a teratoma model. BMC Developmental Biology, 2007, 7, 131.	2.1	17
238	ERK activation causes epilepsy by stimulating NMDA receptor activity. EMBO Journal, 2007, 26, 4891-4901.	3.5	126
239	Clinical presentation and pre-mortem diagnosis of variant Creutzfeldt-Jakob disease associated with blood transfusion: a case report. Lancet, The, 2006, 368, 2061-2067.	6.3	374
240	PTEN, a negative regulator of PI3 kinase signalling, alters tau phosphorylation in cells by mechanisms independent of GSK-3. FEBS Letters, 2006, 580, 3121-3128.	1.3	52
241	Phenotypic heterogeneity in inherited prion disease (P102L) is associated with differential propagation of protease-resistant wild-type and mutant prion protein. Brain, 2006, 129, 1557-1569.	3.7	91
242	Dissociation of pathological and molecular phenotype of variant Creutzfeldt-Jakob disease in transgenic human prion protein 129 heterozygous mice. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 10759-10764.	3.3	68
243	Mutations in the endosomal ESCRTIII-complex subunit CHMP2B in frontotemporal dementia. Nature Genetics, 2005, 37, 806-808.	9.4	752
244	Growth Retardation and Bilateral Cataracts Followed by Anaplastic Meningioma 23 Years after High-Dose Cranial and Whole-Body Irradiation for Acute Lymphoblastic Leukemia: Case Report and Review of the Literature. Journal of Neuro-Oncology, 2005, 74, 195-199.	1.4	10
245	High levels of disease related prion protein in the ileum in variant Creutzfeldt-Jakob disease. Gut, 2005, 54, 1506-1508.	6.1	24
246	An enzymeâ€“detergent method for effective prion decontamination of surgical steel. Journal of General Virology, 2005, 86, 869-878.	1.3	103
247	Disease-related Prion Protein Forms Aggresomes in Neuronal Cells Leading to Caspase Activation and Apoptosis*. Journal of Biological Chemistry, 2005, 280, 38851-38861.	1.6	123
248	An Aneuploid Mouse Strain Carrying Human Chromosome 21 with Down Syndrome Phenotypes. Science, 2005, 309, 2033-2037.	6.0	390
249	Characterization of two distinct prion strains derived from bovine spongiform encephalopathy transmissions to inbred mice. Journal of General Virology, 2004, 85, 2471-2478.	1.3	45
250	Human Prion Protein with Valine 129 Prevents Expression of Variant CJD Phenotype. Science, 2004, 306, 1793-1796.	6.0	246
251	Transgene-driven expression of the Doppel protein in Purkinje cells causes Purkinje cell degeneration and motor impairment. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 3644-3649.	3.3	37
252	Neuroprotective Role of the Reaper-Related Serine Protease HtrA2/Omi Revealed by Targeted Deletion in Mice. Molecular and Cellular Biology, 2004, 24, 9848-9862.	1.1	367

#	Article	IF	Citations
253	Combined Thalidomide and Temozolomide Treatment in Patients with Glioblastoma Multiforme. Journal of Neuro-Oncology, 2004, 67, 191-200.	1.4	88
254	Identification and characterization of a novel mouse prion gene allele. Mammalian Genome, 2004, 15, 383-389.	1.0	26
255	Primary cerebral leiomyosarcoma in a child. Pediatric Radiology, 2004, 34, 495-498.	1.1	22
256	Severe Hypothermia in a Patient with Cerebral Relapse of Whipple?s Disease. Infection, 2004, 32, 119-121.	2.3	5
257	Analysis of 2000 consecutive UK tonsillectomy specimens for disease-related prion protein. Lancet, The, 2004, 364, 1260-1262.	6.3	67
258	Genetic and Expression Profiles of Cerebellar Liponeurocytomas. Brain Pathology, 2004, 14, 281-289.	2.1	69
259	A 38-year-old man with a 9 month history of neurological and cognitive impairment. Lancet Neurology, The, 2003, 2, 189-194.	4.9	2
260	Monoclonal antibodies inhibit prion replication and delay the development of prion disease. Nature, 2003, 422, 80-83.	13.7	457
261	Depleting Neuronal PrP in Prion Infection Prevents Disease and Reverses Spongiosis. Science, 2003, 302, 871-874.	6.0	673
262	Extensive spherical amyloid deposition presenting as a pituitary tumor. Journal of Endocrinological Investigation, 2003, 26, 552-555.	1.8	18
263	Wnt signalling inhibits neural differentiation of embryonic stem cells by controlling bone morphogenetic protein expression. Molecular and Cellular Neurosciences, 2003, 24, 696-708.	1.0	108
264	CNS pathogenesis of prion diseases. British Medical Bulletin, 2003, 66, 131-139.	2.7	18
265	Lhermitte-Duclos Disease in 3 Children: A Clinical Long-Term Observation. Neuropediatrics, 2003, 34, 30-35.	0.3	34
266	Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 6985-6990.	3.3	190
267	Irregular presence of abnormal prion protein in appendix in variant Creutzfeldt-Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 597-598.	0.9	30
268	Histological yield, complications, and technological considerations in 114 consecutive frameless stereotactic biopsy procedures aided by open intraoperative magnetic resonance imaging. Journal of Neurosurgery, 2002, 97, 354-362.	0.9	71
269	Malignant MCLeod myopathy. Muscle and Nerve, 2002, 26, 424-427.	1.0	31
270	PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (Cambridge), 2002, 129, 3513-3522.	1.2	164

#	Article	IF	Citations
271	PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development (Cambridge), 2002, 129, 3513-22.	1.2	86
272	Spongiform encephalopathies: Insights from transgenic models. Advances in Virus Research, 2001, 56, 313-352.	0.9	15
273	Second Primary Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2001, 60, 208-215.	0.9	16
274	Neuroimaging of cerebellar liponeurocytoma. Journal of Neurosurgery, 2001, 95, 324-331.	0.9	39
275	Kell and XK immunohistochemistry in McLeod myopathy. Muscle and Nerve, 2001, 24, 1346-1351.	1.0	63
276	Normal neurogenesis and scrapie pathogenesis in neural grafts lacking the prion protein homologue Doppel. EMBO Reports, 2001, 2, 347-352.	2.0	57
277	Germline SDHD mutation in paraganglioma of the spinal cord. Oncogene, 2001, 20, 5084-5086.	2.6	40
278	Neuroinvasion of Prions: Insights from Mouse Models. Experimental Physiology, 2000, 85, 705-712.	0.9	18
279	Meningeal hemangiopericytoma in childhood. European Radiology, 2000, 10, 1073-1075.	2.3	9
280	Hyperventilation due to mitochondrial myopathy. Journal of the Royal Society of Medicine, 2000, 93, 25-26.	1.1	1
281	Neuroinvasion of prions: insights from mouse models. Experimental Physiology, 2000, 85, 705-712.	0.9	2
282	Malignant Rhabdoid Tumor of the Brain: Quantitative 1H MR-Spectroscopy and Cytogenetics. Neuropediatrics, 2000, 31, 159-161.	0.3	9
283	Differentiation and Histological Analysis of Embryonic Stem Cellâ€Derived Neural Transplants in Mice. Brain Pathology, 2000, 10, 330-341.	2.1	37
284	Prions: Pathogenesis and Reverse Genetics. Annals of the New York Academy of Sciences, 2000, 920, 140-157.	1.8	15
285	Prions: from neurografts to neuroinvasion. , 2000, , 3-12.		3
286	The Heavy Metal-Responsive Transcription Factor-1 (MTF-1) Is Not Required for Neural Differentiation. Biological Chemistry, 1999, 380, 711-5.	1.2	16
287	Ectopic expression of prion protein (PrP) in T lymphocytes or hepatocytes of PrP knockout mice is insufficient to sustain prion replication. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 3987-3992.	3.3	98
288	Shrinking prions: new folds to old questions. Nature Medicine, 1999, 5, 486-487.	15.2	6

#	Article	IF	Citations
289	A crucial role for B cells in neuroinvasive scrapie. Transfusion Clinique Et Biologique, 1999, 6, 17-23.	0.2	16
290	The genetics of prionsâ€"a contradiction in terms?. Lancet, The, 1999, 354, S22-S25.	6.3	8
291	Transgenic and Knockout Mice in Research on Prion Diseases. Brain Pathology, 1998, 8, 715-733.	2.1	38
292	Expression of Amino-Terminally Truncated PrP in the Mouse Leading to Ataxia and Specific Cerebellar Lesions. Cell, 1998, 93, 203-214.	13.5	506
293	A Novel Mitochondrial tRNAPheMutation Inhibiting Anticodon Stem Formation Associated with a Muscle Disease. Biochemical and Biophysical Research Communications, 1998, 247, 112-115.	1.0	44
294	Transgenic mice as research tools in neurocarcinogenesis. Journal of NeuroVirology, 1998, 4, 159-174.	1.0	8
295	Identification of the End Stage of Scrapie Using Infected Neural Grafts. Brain Pathology, 1998, 8, 19-27.	2.1	38
296	The use of transgenic mice in the investigation of transmissible spongiform encephalopathies. OIE Revue Scientifique Et Technique, 1998, 17, 278-290.	0.5	24
297	Scrapie Pathogenesis in Brain Grafts. , 1998, , 187-195.		0
298	Telencephalic Brain Grafts in the Study of Scrapie Pathogenesis. , 1998, , 128-139.		1
299	PrP-expressing tissue required for transfer of scrapie infectivity from spleen to brain. Nature, 1997, 389, 69-73.	13.7	251
300	Astrocyte-specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to hamster scrapie. EMBO Journal, 1997, 16, 6057-6065.	3.5	196
301	Tracking prions: the neurografting approach. Cellular and Molecular Life Sciences, 1997, 53, 485-495.	2.4	6
302	Mice Homozygous for a Modified Î²-Amyloid Precursor Protein (Î²APP) Gene Show Impaired Behavior and High Incidence of Agenesis of the Corpus Callosuma. Annals of the New York Academy of Sciences, 1996, 777, 65-73.	1.8	9
303	Transgenic and knockout mice in the study of neurodegenerative diseases. Journal of Molecular Medicine, 1996, 74, 111-126.	1.7	29
304	Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathology and Applied Neurobiology, 1996, 22, 108-117.	1.8	22
305	Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie.. EMBO Journal, 1996, 15, 1255-1264.	3.5	796
306	Brain cell type specificity and gliosis-induced activation of the human cytomegalovirus immediate-early promoter in transgenic mice. Journal of Neuroscience, 1996, 16, 2275-2282.	1.7	52

#	Article	IF	Citations
307	Normal host prion protein (PrPC) is required for scrapie spread within the central nervous system. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 13148-13151.	3.3	226
308	Comparative in vivo and pathological analysis of the blood-brain barrier in mouse telencephalic transplants. Neuropathology and Applied Neurobiology, 1996, 22, 118-128.	1.8	20
309	Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nature Genetics, 1996, 12, 195-199.	9.4	156
310	Normal host prion protein necessary for scrapie-induced neurotoxicity. Nature, 1996, 379, 339-343.	13.7	756
311	Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathology and Applied Neurobiology, 1996, 22, 108-117.	1.8	3
312	Prion protein (PrP) with amino-proximal deletions restoring susceptibility of PrP knockout mice to scrapie. EMBO Journal, 1996, 15, 1255-64.	3.5	420
313	Telencephalic transplants in mice: characterization of growth and differentiation patterns. Neuropathology and Applied Neurobiology, 1996, 22, 108-17.	1.8	7
314	Comparative in vivo and pathological analysis of the blood-brain barrier in mouse telencephalic transplants. Neuropathology and Applied Neurobiology, 1996, 22, 118-28.	1.8	6
315	Neuroectodermal grafting: a new tool for the study of neurodegenerative diseases. Histology and Histopathology, 1996, 11, 1063-73.	0.5	10
316	Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma. Journal of Neuropathology and Experimental Neurology, 1995, 54, 91-95.	0.9	306
317	Transgenic and gene disruption techniques in the study of neurocarcinogenesis. Glia, 1995, 15, 348-364.	2.5	23
318	The AMOG/Î²2 subunit of Na, K-ATPase is not necessary for long-term survival of telencephalic grafts. Glia, 1995, 15, 377-388.	2.5	18
319	Secondary manifestation of medulloblastoma: Metastases and local recurrences in 66 patients. Acta Neurochirurgica, 1995, 136, 117-126.	0.9	25
320	Symptomatic cerebellar metastasis and late local recurrence of a cauda equina paraganglioma. Journal of Neurosurgery, 1995, 83, 166-169.	0.9	44
321	Activation of HIV transcription by human foamy virus in transgenic mice. Laboratory Investigation, 1995, 73, 103-10.	1.7	9
322	Microsatellite analysis of loss of heterozygosity on chromosomes 9q, 11 p and 17p in medulloblastomas. Neuropathology and Applied Neurobiology, 1994, 20, 74-81.	1.8	58
323	Behavioral and anatomical deficits in mice homozygous for a modified ?-amyloid precursor protein gene. Cell, 1994, 79, 755-765.	13.5	294
324	Transgenic and Knockâ€out Mice: Models of Neurological Disease. Brain Pathology, 1994, 4, 3-20.	2.1	59

#	Article	IF	Citations
325	Functional organization of the auditory thalamus in the guinea pig. Experimental Brain Research, 1991, 86, 384-92.	0.7	35
326	The projection from medial geniculate to field AI in cat: organization in the isofrequency dimension. Journal of Neuroscience, 1990, 10, 50-61.	1.7	58
327	Anatomy of the auditory thalamocortical system of the guinea pig. Journal of Comparative Neurology, 1989, 282, 489-511.	0.9	115
328	Prognostic value of test(s) for O⁶ -methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. The Cochrane Library, 0, , .	1.5	2